Repligen Corporation to Present at Upcoming March Conferences
Rhea-AI Summary
Repligen (NASDAQ:RGEN) will participate in three investor conferences in March 2026: Leerink Global Healthcare (Mar 8–11), Barclays Global Healthcare (Mar 10–12) and KeyBanc Virtual Healthcare Forum (Mar 17–18). Executives Jason Garland and Olivier Loeillot will take part in analyst-led discussions on March 10–11 and March 18, with live webcasts for Leerink and KeyBanc available on the company investor relations website and replayable for a limited time.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
RGEN is up 2.26% while key peers are mixed: STVN up 8.49%, but TFX, BLCO, ATR, and MMSI are down between about 0.8–3%, suggesting today’s move is more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 24 | Earnings and guidance | Positive | -0.5% | Q4 and full-year 2025 beat with upbeat 2026 revenue and margin guidance. |
| Feb 10 | Earnings date set | Neutral | -0.4% | Announcement of date and time for Q4 and full-year 2025 results call. |
| Jan 06 | Board leadership change | Neutral | +1.7% | Executive chair retirement with experienced director elected as new board chair. |
| Dec 18 | Conference presentation | Neutral | +0.5% | Participation and company overview at J.P. Morgan 2026 Healthcare Conference. |
| Dec 16 | Product launch | Positive | -1.6% | Launch of three next‑generation chromatography resins for gene therapy workflows. |
Recent positive fundamental and product news has twice coincided with next-day share declines, while neutral calendar/leadership updates have generally seen small gains or mild moves.
Over the past few months, Repligen reported strong Q4 and full-year 2025 results with $738M revenue and raised 2026 guidance, yet shares slipped slightly after that earnings release. Earlier, the company announced board leadership changes and new chromatography resins to support next‑generation modalities, with mixed but generally modest price reactions. It also highlighted conference participation at the J.P. Morgan 2026 Healthcare Conference. Today’s conference-focused announcement fits a pattern of routine investor-relations visibility alongside ongoing product and financial updates.
Market Pulse Summary
This announcement highlights Repligen’s participation in three March 2026 healthcare investor conferences, with both the CFO and CEO presenting and webcasts available via the investor relations site. It follows recent earnings, product, and governance updates that produced generally modest price moves and occasional divergences from positive fundamentals. Investors may focus on management’s commentary at these events, particularly around growth drivers, integration of recent acquisitions, and progress versus the company’s 2026 financial guidance.
AI-generated analysis. Not financial advice.
WALTHAM, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating in three upcoming investor conferences.
- The Leerink Global Healthcare Conference, being held March 8 – 11 in Miami. Jason Garland, Chief Financial Officer, will participate in an analyst led discussion at 11:20 a.m. ET on Tuesday, March 10, 2026.
- The Barclays 28th Annual Global Healthcare Conference, being held March 10 – 12 in Miami. Jason Garland, Chief Financial Officer, will participate in an analyst led discussion at 10:30 a.m. ET on Wednesday, March 11, 2026.
- The 2026 KeyBanc Virtual Healthcare Forum, being held March 17 – 18. Olivier Loeillot, President and Chief Executive Officer, will participate in an analyst led discussion at 2:15 p.m. ET on Wednesday, March 18, 2026.
A live webcast of the Leerink and KeyBanc presentations will be accessible through Repligen’s Investor Relations website at www.repligen.com, and will be available for replay for a limited period of time following the events.
About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the company see our website at www.repligen.com, and follow us on LinkedIn.
Repligen Contact:
Jacob Johnson
VP, Investor Relations
781-419-0204
investors@repligen.com
FAQ
When will Repligen (RGEN) present at the Leerink Global Healthcare Conference in March 2026?
What time is Repligen (RGEN) scheduled to speak at the Barclays Global Healthcare Conference on March 11, 2026?
Will Repligen (RGEN) provide a webcast of its March 2026 conference presentations?
Who from Repligen (RGEN) will speak at the 2026 KeyBanc Virtual Healthcare Forum and when?
How can investors access Repligen's (RGEN) conference replays after the March 2026 events?
Which Repligen (RGEN) executives are speaking at the March 2026 investor conferences?
